Group 1 - The core point of the article is that Yejv Medical (6929.HK) has completed the structural topping of its R&D and production facility in Fuyang, Hangzhou, which is set to be the largest integrated facility globally, with full production expected by 2027 [1] - The new facility will add approximately 2.4 million units of production capacity annually, increasing the total annual output from the current 2.1 million units of balloons and stents [1] - The company currently operates R&D centers, production bases, and logistics hubs in China, Germany, Japan, and the Netherlands, and has a sales network covering over 70 countries and regions [1][1] Group 2 - Yejv Medical holds over 250 authorized patents and has announced patent applications, with more than 55 approved products sold in major global markets [1][1] - The completion of the Hangzhou facility is expected to significantly enhance the company's high-quality production capacity, accelerate the incubation and application of new technologies, and improve the stability of the global supply chain and overall competitiveness [1] - The company aims to capitalize on the continuous growth opportunities in the global PCI and PTA device markets [1]